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Abstract 
Lornoxicam is a non steroidal anti-inflammatory drug with analgesic 
properties and belongs to the class oxicams. It is extremely bitter in taste. The 
purpose of this research was to develop a bitterless oral disintegrating tablet 
of Lornoxicam. Taste masking was done by complexing Lornoxicam with 
aminoalkyl methacrylate copolymer (Eudragit EPO) in different ratios. In 
vitro release profile obtained at pH 6.2 indicate that perceivable amount of 
drug will not be released in saliva while high percentage release (more than 
80 % in 30 mins.) would be obtained at acidic pH 1.2 of the stomach. Three 
super disintegrants were used while preparing the tablets e.g. sodium starch 
glycolate, crospovidone and crosscarmellose sodium. The tablets were 
evaluated for different properties like drug content, hardness, friability and 
disintegration time. The tablets shown good taste and disintegration in oral 
cavity. 
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Introduction 
In recent decades, a variety of pharmaceutical 
research has been conducted to develop new dosage 
forms. Considering quality of life, most of these 
efforts have been focused on ease of medication. 
Among the various dosage forms developed to 
improve the ease of administration, the oral 
disintegrating tablet (ODT) is the most widely 
preferred commercial products [1, 2]. 
 
The ODT has remarkable disintegration properties; it 
can rapidly disintegrate without water in the mouth 
within a few seconds. When an ODT is placed in the 
oral cavity, saliva quickly penetrates into the pores 
causing rapid disintegration [3]. The ODT presents 
considerable advantages for the patient (or elder) who  
 
can not swallow (Dysphagia), or who is not permitted 
water intake because of disease.  Such tablets can be 
produced by various methods; Namely, 1) drying 
after filling the pockets of the press through pack 
(PTP) with dispersed solution of the drug, 2) drying 
after low-pressure compression of humid powder 
granules containing the drug,  3) compression of dry 
powder granules containing the drug and, shaping by 
direct compression after mixing excipients and the 
drug [4]. 
 
Lornoxicam is a non steroidal anti-inflammatory drug 
with analgesic properties and belongs to the class 
oxicams. The mode of action of Lornoxicam is partly 
based on inhibition of prostaglandin synthesis 
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(inhibition of the cyclo-oxygenase enzyme). 
Lornoxicam is absorbed rapidly and almost 
completely from the gastro-intestinal tract [5]. 
Lornoxicam is very bitter in taste and yet no oral 
disintegrating taste-masked preparation is available in 
market, which might be helpful in pediatric and 
geriatric patients. Therefore, to provide this drug in a 
more accessible and patient compliant form, in the 
present study an attempt has been made to mask its 
bitter taste and formulate it into oral disintegrating 
tablet [6]. 
 
Materials and Methods 
Lornoxicam was a gift from Hetero drugs Ltd. 
(Hyderabad, India). Aminoalkyl methacrylate 
copolymer (Eudragit EPO) was a gift from Degussa 
India Private Ltd (Mumbai, India). Croscarmellose 
sodium, sodium starch glycolate, crospovidone, 
crosscarmellose sodium and microcrystalline 
cellulose IP were obtained as gift samples from 
Torrent Pharmaceuticals Ltd (Ahmedabad, India). 
Other chemicals and reagent used were of AR grade. 
 
Preparation of taste masked granules of 
Lornoxicam 
 
Lornoxicam was thoroughly mixed with powdered 
Eudragit EPO in different ratios. Then 10 % Isopropyl 
alcohol (IPA) was added to this mixture in a glass 
beaker and mixed well to make a gelatinous mass. 
The prepared gel was manually extruded using a 
syringe. After extrusion of the gel, IPA was removed 
by evaporation overnight at room temperature. 
Subsequently the solidified drug polymer complex 
(DPC) was crushed into granules using a mortar. 
Three batches were prepared containing drug-
Eudragit EPO in the ratio of 1:1, 1:2, and 1:3 in IPA 
by the above-mentioned method. [7,8] 
 
 
Characterization of DPC Drug Content, In Vitro 
Taste Evaluation 
Drug content was determined by dissolving 100 mg 
of DPC in 500 mL of simulated gastric fluid (SGF) 
and analyzing 1mL of appropriately diluted sample at 
265 nm (Table 1). 
 
In vitro taste was evaluated by determining drug 
release in simulated salivary fluid (SSF) (pH 6.2) to 
predict release in the human saliva. DPC, equivalent 
to 8 mg of Lornoxicam (i.e., its dose), was placed in 
10 mL of SSF and shaken for 60 seconds. The amount 
of drug released was analyzed at 265 nm (Table 1). 
 
On the basis of these observations Drug polymer ratio 
1:3 was finalized for further study [3]. 
 
 
Table-1 Drug Content and In Vitro Taste Evaluation of 
DPCS in SSF 
 
 
 *Results are the mean of 3 observations ± SD. 
 
 
Formulation of oral disintegrating tablets (ODTs) 
 
Direct compression method was used to prepare the 
ODTs of Lornoxicaml: Eudragit EPO complex. 
Different excipients incorporated are Mannitol, 
Avicel PH 102 (as diluent), Aerosil (as lubricant) and 
Aspartame (as sweetener). Superdisintegrants such as, 
crosscarmellose sodium, crospovidone and sodium 
starch glycolate were also used in different 
concentrations [9, 10] (Table-2). 
 
 
Evaluation of ODTs 
 
Hardness 
 It is the tensile strength of tablets expressed in 
kg/cm2. It is the pressure required to break the tablet 
in to two halves by compression [11]. 
 
Weight Variation 
Weight variation test is done with 20 tablets. It is the 
individual variation of tablet weight from the average 
weight of 20 tablets [12]. 
 
Serial 
No. 
Drug-Polymer 
Ratio in DPC 
% drug content 
in DPC* 
% Drug Dissolved 
in SSF* 
1. 1:1 94.21 ± 0.48 45 ± 0.32 
2. 1:2 49.52 ± 0.05 19 ± 0.21 
3. 1:3 31.85 ± 0.32 4.60 ± 0.42 
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Table-2 Formulation table of batch F1-F6 
 
 
 
Friability 
This test is performed to know the effect of friction 
and shocks on tablets. Preweighed sample of tablets 
was placed in the friabilator (Roche friabilator), and 
operated for 100 revolutions. Tablets were dusted and 
reweighed. The test complies if tablets not loose more 
than 1% of their weigh [13]. 
  
Content Uniformity 
Five tablets were crushed and from this, quantity 
equivalent to 8 mg of lornoxicam was dissolved in 
suitable quantity of pH 1.2 solution. Solution was 
filtered and diluted and analyzed for drug content 
[14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disintegration Time 
Disintegration time for ODTs was determined using 
USP disintegration apparatus with SSF (pH 6.2, 900 
ml at 37°C) as the disintegrating medium. To comply 
the test all tablets should disintegrate within 3 
minutes [15]. 
 
Dissolution Study of Tablets 
On the basis of disintegration data, formulation F6 
was chosen for dissolution study, as it was showing 
least disintegration time i.e. 38 seconds. In vitro 
dissolution study on prepared tablets was performed 
in SSF (pH 6.2) and SGF (pH 1.2) without enzymes 
using USP type II (paddle) apparatus operated at 50 
rpm (900 ml) for 60 minutes (37 ± 0.5°C).[16] 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig-1 Dissolution profile of batch F6 
 
 
 
 
 
 
 
 
 
 
 
Formulations and their excipients (mg) 
Ingredients 
F1 F2 F3 F4 F5 F6 
DPC equivalent to 8 mg 
of drug 25.2 25.2 25.2 25.2 25.2 25.2 
Mannitol 66 61 66 61 66 61 
Avicel PH 102 45 45 45 45 45 45 
Sodium Starch Glycolate 2 7 - - - - 
Crospovidone - - 2 7 - - 
Crosscarmellose Sodium - - - - 2 7 
Aerosil 1.8 1.8 1.8 1.8 1.8 1.8 
Aspartame 5 5 5 5 5 5 
Tablet Weight 145 145 145 145 145 145 
Formulation 
No. 
Hardness 
(kg/cm2) 
Friability 
(%) 
Weight 
variation 
Thickness 
(mm) ±S.D 
Drug Content 
(%) 
Disintegration 
time(sec) 
F1 3.96± 0.01 0.28 Passes 2.51± 0.1 101.21 1 min. 25 sec. 
F2 4.00± 0.01 0.21 Passes 2.49± 0.1 100.07 56 sec. 
F3 3.94± 0.01 0.31 Passes 2.55± 0.1 99.90 1 min. 15 sec. 
F4 4.06± 0.005 0.18 Passes 2.48± 0.1 100.12 52 sec. 
F5 3.96± 0.01 0.24 Passes 2.54± 0.1 98.95 1 min 05 sec. 
F6 4.04± 0.01 0.21 Passes 2.48± 0.1 100.25 38 sec. 
Table-3 Evaluation of various batches of ODTs 
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Results and Discussion 
 
Eudragit EPO was chosen for the taste masking of 
Lornoxicam. The Drug-polymer complex (taste-
masked granules) was prepared by simple mass 
extrusion technique using syringe [7]. The drug 
polymer ratio that gave the best taste masking was 
1:3. Drug content was found to be 31.85 % in the 
complex (Table-1). 
 
Six formulations F1-F6 were prepared using various 
excipients and three different superdisintegrants 
(crosscarmellose sodium, crospovidone and sodium 
starch glycolate) in different concentrations. 
 
ODTs were prepared by direct compression [9, 10] 
and evaluated for Hardness [11], weight 
variation[12], friability[13], content uniformity[14], 
disintegration time [15] and dissolution [16]. The % 
drug content was found in the range of 98.95 - 
101.21% (within the acceptable range) and the 
hardness was found between 3.94 - 4.06 kg/cm2. 
Thickness of ODTs was found in between 2.48-2.4 
mm. Friability of was found below 1% indicating 
good resistance against mechanical shear (Table-3). 
 
Among the different formulations, F- 6 was chosen as 
optimized batch containing crosscarmellose sodium 
as superdisintegrant, as it has produced the ODT 
having least disintegration time of 33 sec. The 
dissolution study was carried out in SSF and SGF, 
yielding about 10% and 90% dissolution respectively 
in 60 minutes. These results shown that taste masking 
effective  
 
On the basis of above results it can be concluded that 
an oral disintegrating tablet of Lornoxicam can be 
prepared. Eudragit EPO also found to be efficient in 
taste-masking. 
 
Acknowledgements 
 
The authors are thankful to Hetero drugs Ltd. 
(Hyderabad, India) for the gift sample of lornoxicam 
Degussa India Private Ltd (Mumbai, India) for 
Aminoalkyl methacrylate copolymer (Eudragit EPO) 
and Torrent Pharmaceuticals Ltd (Ahmedabad, India) 
for Croscarmellose sodium, sodium starch glycolate, 
crospovidone, crosscarmellose sodium and 
microcrystalline cellulose IP. 
 
 
References 
 
1. Chang R, Guo X, Burnside B, Couch R. A review 
of fast dissolving tablets. Pharm Tech. (North 
America). 2000;52-58. 
 
2. Bi Y, Sunada H, Yonezawa Y, Dayo K, Otsuka A, 
Iida K. Preparation and evaluation of a 
compressed tablet rapidly disintegrating in oral 
cavity. Chem Pharm Bull (Tokyo). 1996;44:2121-
2127. 
 
3. Watanabe Y, Ishikawa Y, Utoguchi N. 
Matsumoto M. Preparation and evaluation of 
tablets rapidly disintegrating in saliva containing 
bitter taste masked granules by the compression 
method. Chem. Pharm. Bull. 1999; 47:1451-1457. 
 
4. Kaushik D, Dureja H, Saini TR. Mouth dissolving 
tablets: A review. Indian Drugs-Bombay. 2004; 
41: 187-193. 
 
5. Balfour JA, Fitton A, Barradell LB. Lornoxicam. 
A review of its pharmacology and therapeutic 
potential in the management of painful and 
inflammatory conditions. Drugs. 1996;51(4):639-
57. 
 
6. Lorenz IH, Egger K, Schubert H, Schnürer C, 
Tiefenthaler W, Hohlrieder M, Schocke MF, 
Kremser C, Esterhammer R, Ischebeck A, Moser 
PL,  Kolbitsch C. Lornoxicam characteristically 
modulates cerebral pain-processing in human 
volunteers: a functional magnetic resonance 
imaging study. British Journal of Anaesthesia 
2008; 100(6):827-833. 
 
7. Makooi-Morehead WT, Buehler JD, Landmann, 
BR. US Patent No., US6238695, 2001. 
 
 
 30
Jadon et al: International Journal of Drug Delivery 1(2009) 27-31 
 
8. Watanabe Y., Ishikawa Y., Utoguchi N. and 
Matsumoto M. Preparation and evaluation of 
tablets rapidly disintegrating in saliva containing 
bitter taste masked granules by the compression 
method. Chem. Pharm. Bull., 1999, 47, 1451-
1457. 
 
9. Cousin G, Bruna E, Gendrot E, US Patent No., 
US5464632, 1995. 
 
10. Kibbe A., In; Handbook of Pharmaceutical 
Excipients, 3rd Edn., The Pharmaceutical Press, 
London; 2000, p 501. 
 
11. Goodhart FW, Draper JR, Dancz D, Ninger FC. 
Evaluation of tablet breaking strength testers. J 
Pharm Sci 1973; 62(2): 297-304 
 
12. Sreenivas SA, Gadad AP. Formulation and 
evaluation of Ondancetron Hcl directly 
compressed mouth disintegrating tablets. Indian 
Drugs, 2006; 43(1):35-38. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13. Banker GS, Anderson NR. In; Lachman, L, 
Lieberman, HA, Kanig, JL, Eds., The Theory and 
Practice of Industrial Pharmacy, 3rd Edn., Lea and 
Febiger, Philadelphia; 1991, p 293. 
 
14. Aley AM, Semreen M, Qato MK. To produce 
rapidly disintegrating Tenoxicam tablet via 
Camphor sublimation. Pharmaceutical 
Technology, 2005; p 68-78. 
 
15. Bi Y, Sunanda H, Yonezawa Y, Danjo K, Otsuka 
A, Iida K. Preparation and evaluation of a 
compressed tablet rapidly disintegrating in the 
oral cavity. Chem. Pharm. Bull., 1996, 44: 2121-
2127 
 
16. Reddy LH, Gosh BR. Fast dissolving drug 
delivery system: A Review of the literature. 
Indian J Pharm Sci. 2002;64: 331-336. 
 
 31
